You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameIndomethacin
Accession NumberDB00328  (APRD00109)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionIndomethacin is a non-steroidal antiinflammatory agent (NSAIA) with antiinflammatory, analgesic and antipyretic activity. Its pharmacological effect is thought to be mediated through inhibition of the enzyme cyclooxygenase (COX), the enzyme responsible for catalyzes the rate-limiting step in prostaglandin synthesis via the arachidonic acid pathway.
Structure
Thumb
Synonyms
{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methyl-1H-indol-3-yl}acetic acid
1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid
Aconip
Indocin
Indometacin
Indometacina
Indometacine
Indometacinum
Indomethacin
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ftp-indomethacincapsule25 mgoralFtp Pharmacal Inc.1998-10-092004-08-03Canada
Ftp-indomethacincapsule50 mgoralFtp Pharmacal Inc.1998-10-092004-08-03Canada
Indocid Cap 25mgcapsule25 mgoralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1965-12-311998-08-14Canada
Indocid Cap 50mgcapsule50 mgoralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1970-12-311998-08-14Canada
Indocid SR 75mgcapsule (sustained-release)75 mgoralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1980-12-311999-08-06Canada
Indocid Sterile Oph Susp 1%drops10 mgophthalmicMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1983-12-311999-08-06Canada
Indocid Sup 100mgsuppository100 mgrectalMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1971-12-312003-08-08Canada
Indocid Sup 50mgsuppository50 mgrectalMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1983-12-312003-08-08Canada
Indocinsuspension25 mg/5mLoralIroko Pharmaceuticals, LLC1985-10-10Not applicableUs
Indocollyreliquid; powder for solution1 mgophthalmicLaboratoire Chauvin S.A.1997-02-132001-01-19Canada
Indomethacincapsule25 mg/1oralCarilion Materials Management2010-07-30Not applicableUs
Indomethacincapsule25 mg/1oralMylan Pharmaceuticals Inc.1984-04-20Not applicableUs
Indomethacincapsule25 mg/1oralREMEDYREPACK INC.2015-06-19Not applicableUs
Indomethacincapsule25 mg/1oralMylan Institutional Inc.1998-09-10Not applicableUs
Indomethacincapsule25 mg/1oralContract Pharmacy Services Pa2010-07-30Not applicableUs
Indomethacincapsule25 mg/1oralHeritage Pharmaceuticals Inc.2010-07-30Not applicableUs
Indomethacincapsule25 mg/1oralLiberty Pharmaceuticals, Inc.2013-04-23Not applicableUs
Indomethacincapsule50 mg/1oralDIRECT RX2015-01-01Not applicableUs
Indomethacincapsule25 mg/1oralPhysicians Total Care, Inc.2004-08-02Not applicableUs
Indomethacincapsule25 mg/1oralPreferred Pharmaceuticals, Inc.2010-07-30Not applicableUs
Indomethacincapsule25 mg/1oralClinical Solutions Wholesale, Llc2010-07-30Not applicableUs
Indomethacincapsule50 mg/1oralHeritage Pharmaceuticals Inc.2010-07-30Not applicableUs
Indomethacincapsule25 mg/1oralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
Indomethacincapsule25 mg/1oralProficient Rx LP2010-07-30Not applicableUs
Indomethacincapsule25 mg/1oralCardinal Health2010-10-29Not applicableUs
Indomethacincapsule25 mg/1oralREMEDYREPACK INC.2013-03-18Not applicableUs
Indomethacincapsule50 mg/1oralPreferred Pharmaceuticals, Inc.2010-07-30Not applicableUs
Indomethacincapsule50 mg/1oralClinical Solutions Wholesale, Llc2010-07-30Not applicableUs
Indomethacincapsule25 mg/1oralPd Rx Pharmaceuticals, Inc.2010-07-30Not applicableUs
Indomethacincapsule25 mg/1oralSTAT Rx USA LLC2010-09-15Not applicableUs
Indomethacininjection, powder, lyophilized, for solution1 mg/mLintravenousFresenius Kabi USA, LLC2010-03-19Not applicableUs
Indomethacincapsule50 mg/1oralPd Rx Pharmaceuticals, Inc.2010-09-15Not applicableUs
Novo-methacin - 100mg Supsuppository100 mgrectalNovopharm Limited1995-12-312005-08-10Canada
Novo-methacin - Sup 50mgsuppository50 mgrectalNovopharm Limited1995-12-312005-08-10Canada
Ntp-indomethacincapsule50 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-indomethacincapsule25 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Nu-indo Cap 25mgcapsule25 mgoralNu Pharm Inc1990-12-312012-09-04Canada
Nu-indo Cap 50mgcapsule50 mgoralNu Pharm Inc1990-12-312012-09-04Canada
Pro-indo 25 Cap 25mgcapsule25 mgoralPro Doc Limitee1985-12-312014-07-24Canada
Pro-indo 50 Cap 50mgcapsule50 mgoralPro Doc Limitee1985-12-312014-07-24Canada
Ratio-indomethacinsuppository100 mgrectalTeva Canada Limited1993-12-31Not applicableCanada
Ratio-indomethacincapsule25 mgoralRatiopharm Inc Division Of Teva Canada Limited1997-01-212006-08-04Canada
Ratio-indomethacincapsule50 mgoralRatiopharm Inc Division Of Teva Canada Limited1997-01-212006-08-04Canada
Ratio-indomethacinsuppository50 mgrectalRatiopharm Inc Division Of Teva Canada Limited1993-12-312006-08-04Canada
Rhodacine - Cap 25mgcapsule25 mgoralRhodiapharm Inc1996-11-282001-07-20Canada
Rhodacine - Cap 50mgcapsule50 mgoralRhodiapharm Inc1996-11-282001-07-20Canada
Rhodacine - Sup 100mgsuppository100 mgrectalRhoxalpharma Inc1995-12-312009-11-24Canada
Rhodacine - Sup 50mgsuppository50 mgrectalRhoxalpharma Inc1995-12-312009-11-24Canada
Sandoz Indomethacinsuppository50 mgrectalSandoz Canada Incorporated1997-11-17Not applicableCanada
Sandoz Indomethacinsuppository100 mgrectalSandoz Canada Incorporated1997-11-17Not applicableCanada
Teva-indomethacincapsule25 mgoralTeva Canada Limited1980-12-31Not applicableCanada
Teva-indomethacincapsule50 mgoralTeva Canada Limited1980-12-31Not applicableCanada
Tivorbexcapsule20 mg/1oralIroko Pharmaceuticals, LLC2015-07-06Not applicableUs
Tivorbexcapsule40 mg/1oralIroko Pharmaceuticals, LLC2015-07-06Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Indomethacin Cap 25mgcapsule25 mgoralApotex Inc1984-12-31Not applicableCanada
Apo Indomethacin Cap 50mgcapsule50 mgoralApotex Inc1984-12-31Not applicableCanada
Indocinsuppository50 mg/1rectalIroko Pharmaceuticals, LLC1992-08-31Not applicableUs
Indomethacincapsule50 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2010-12-22Not applicableUs
Indomethacincapsule50 mg/1oralSandoz Inc1987-04-29Not applicableUs
Indomethacincapsule25 mg/1oralA S Medication Solutions Llc2011-11-01Not applicableUs
Indomethacincapsule50 mg/1oralPhysicians Total Care, Inc.1999-07-27Not applicableUs
Indomethacincapsule50 mg/1oralbryant ranch prepack2010-07-30Not applicableUs
Indomethacincapsule50 mg/1oralSTAT Rx USA LLC2010-07-16Not applicableUs
Indomethacincapsule25 mg/1oralTeva Pharmaceuticals USA Inc2007-12-14Not applicableUs
Indomethacincapsule50 mg/1oralREMEDYREPACK INC.2011-10-25Not applicableUs
Indomethacincapsule50 mg/1oralMylan Institutional Inc.1998-09-15Not applicableUs
Indomethacincapsule50 mg/1oralContract Pharmacy Services Pa2010-07-30Not applicableUs
Indomethacincapsule25 mg/1oralAv Pak2015-05-19Not applicableUs
Indomethacincapsule25 mg/1oralCaraco Pharmaceutical Laboratories, Ltd.2013-05-16Not applicableUs
Indomethacincapsule25 mg/1oralHetero Drugs Ltd.,2011-04-12Not applicableUs
Indomethacincapsule25 mg/1oralRebel Distributors Corp2010-07-30Not applicableUs
Indomethacincapsule, extended release75 mg/1oralBlenheim Pharmacal, Inc.2015-07-14Not applicableUs
Indomethacincapsule, extended release75 mg/1oralPaddock Laboratories, LLC2010-11-30Not applicableUs
Indomethacincapsule, extended release75 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-21Not applicableUs
Indomethacincapsule25 mg/1oralREMEDYREPACK INC.2013-09-26Not applicableUs
Indomethacincapsule50 mg/1oralDIRECT RX2014-01-01Not applicableUs
Indomethacincapsule25 mg/1oralCamber Pharmaceuticals2011-11-01Not applicableUs
Indomethacincapsule25 mg/1oralLake Erie Medical DBA Quality Care Products LLC2007-12-14Not applicableUs
Indomethacincapsule50 mg/1oralBlenheim Pharmacal, Inc.2012-08-13Not applicableUs
Indomethacincapsule25 mg/1oralA S Medication Solutions Llc2011-11-01Not applicableUs
Indomethacincapsule75 mg/1oralPhysicians Total Care, Inc.1995-04-26Not applicableUs
Indomethacincapsule25 mg/1oralbryant ranch prepack2010-07-30Not applicableUs
Indomethacincapsule25 mg/1oralREMEDYREPACK INC.2014-08-26Not applicableUs
Indomethacincapsule25 mg/1oralRed Pharm Drug Inc.2010-07-16Not applicableUs
Indomethacincapsule25 mg/1oralRebel Distributors Corp2010-12-22Not applicableUs
Indomethacincapsule50 mg/1oralTeva Pharmaceuticals USA Inc2007-12-14Not applicableUs
Indomethacincapsule50 mg/1oralREMEDYREPACK INC.2011-09-08Not applicableUs
Indomethacincapsule25 mg/1oralREMEDYREPACK INC.2013-03-26Not applicableUs
Indomethacincapsule, extended release75 mg/1oralKvk Tech, Inc.2012-07-27Not applicableUs
Indomethacincapsule50 mg/1oralAv Pak2015-05-20Not applicableUs
Indomethacincapsule50 mg/1oralCaraco Pharmaceutical Laboratories, Ltd.2013-05-16Not applicableUs
Indomethacincapsule50 mg/1oralHetero Drugs Ltd.,2011-04-12Not applicableUs
Indomethacincapsule25 mg/1oralPd Rx Pharmaceuticals, Inc.2010-12-22Not applicableUs
Indomethacinsuppository50 mg/1rectalG & W LABORATORIES, INC.1992-08-31Not applicableUs
Indomethacincapsule50 mg/1oralA S Medication Solutions Llc2011-11-01Not applicableUs
Indomethacincapsule50 mg/1oralREMEDYREPACK INC.2014-05-07Not applicableUs
Indomethacincapsule, extended release75 mg/1oralDIRECT RX2015-01-01Not applicableUs
Indomethacincapsule50 mg/1oralGlenmark Pharmaceuticals Inc., Usa2010-12-22Not applicableUs
Indomethacincapsule50 mg/1oralCamber Pharmaceuticals2011-11-01Not applicableUs
Indomethacincapsule25 mg/1oralPd Rx Pharmaceuticals, Inc.2010-09-15Not applicableUs
Indomethacincapsule, extended release75 mg/1oralbryant ranch prepack2010-12-06Not applicableUs
Indomethacincapsule50 mg/1oralA S Medication Solutions2011-11-01Not applicableUs
Indomethacincapsule50 mg/1oralBlenheim Pharmacal, Inc.2010-11-08Not applicableUs
Indomethacincapsule25 mg/1oralA S Medication Solutions Llc2010-12-22Not applicableUs
Indomethacincapsule, extended release75 mg/1oralREMEDYREPACK INC.2012-03-01Not applicableUs
Indomethacincapsule50 mg/1oralREMEDYREPACK INC.2013-05-13Not applicableUs
Indomethacincapsule, extended release75 mg/1oralREMEDYREPACK INC.2015-10-28Not applicableUs
Indomethacincapsule50 mg/1oralRed Pharm Drug Inc.2007-04-01Not applicableUs
Indomethacincapsule50 mg/1oralRebel Distributors Corp1986-02-12Not applicableUs
Indomethacincapsule, extended release75 mg/1oralEon Labs, Inc.1998-05-28Not applicableUs
Indomethacincapsule, extended release75 mg/1oralActavis Inc.2013-12-17Not applicableUs
Indomethacincapsule, extended release75 mg/1oralAv Pak2015-09-15Not applicableUs
Indomethacincapsule25 mg/1oralClinical Solutions Wholesale2007-12-14Not applicableUs
Indomethacincapsule50 mg/1oralMed Vantx, Inc.2007-12-14Not applicableUs
Indomethacincapsule, extended release75 mg/1oralCamber Pharmaceuticals, Inc.2012-09-28Not applicableUs
Indomethacincapsule25 mg/1oralSandoz Inc1987-04-29Not applicableUs
Indomethacincapsule50 mg/1oralA S Medication Solutions Llc2011-11-01Not applicableUs
Indomethacincapsule, extended release75 mg/1oralA S Medication Solutions Llc2012-07-27Not applicableUs
Indomethacincapsule50 mg/1oralProficient Rx LP2011-11-01Not applicableUs
Indomethacincapsule25 mg/1oralGlenmark Pharmaceuticals Inc., Usa2010-12-22Not applicableUs
Indomethacincapsule25 mg/1oralA S Medication Solutions Llc2010-12-22Not applicableUs
Indomethacincapsule, extended release75 mg/1oralPd Rx Pharmaceuticals, Inc.2012-07-27Not applicableUs
Indomethacincapsule, extended release75 mg/1oralAmneal Pharmaceuticals of New York, LLC2010-12-06Not applicableUs
Indomethacincapsule25 mg/1oralA S Medication Solutions2010-12-22Not applicableUs
Indomethacincapsule50 mg/1oralRebel Distributors Corp2010-12-22Not applicableUs
Indomethacincapsule, extended release75 mg/1oralBlenheim Pharmacal, Inc.2015-06-01Not applicableUs
Indomethacincapsule50 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-04-20Not applicableUs
Indomethacincapsule25 mg/1oralREMEDYREPACK INC.2013-06-17Not applicableUs
Indomethacincapsule25 mg/1oralDIRECT RX2014-01-01Not applicableUs
Indomethacincapsule, extended release75 mg/1oralAmerican Health Packaging2010-03-26Not applicableUs
Indomethacincapsule50 mg/1oralREMEDYREPACK INC.2013-03-18Not applicableUs
Indomethacincapsule50 mg/1oralMylan Pharmaceuticals Inc.1984-04-20Not applicableUs
Indomethacincapsule25 mg/1oralREMEDYREPACK INC.2010-12-06Not applicableUs
Indomethacincapsule50 mg/1oralUnit Dose Services2011-11-01Not applicableUs
Indomethacincapsule50 mg/1oralClinical Solutions Wholesale2007-12-14Not applicableUs
Indomethacincapsule, extended release75 mg/1oralDispensing Solutions, Inc.2010-12-06Not applicableUs
Indomethacin ERcapsule75 mg/1oralApotheca, Inc.2010-03-04Not applicableUs
Indomethacin ERcapsule75 mg/1oralApotheca, Inc.2006-05-02Not applicableUs
Indomethacin Extended-releasecapsule75 mg/1oralJubilant Cadista Pharmaceuticals Inc.2015-10-05Not applicableUs
Indomethacin Extended-releasecapsule75 mg/1oralKeltman Pharmaceuticals Inc.2006-01-09Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ArthrexinAlphapharm
ElmetacinSankyo
IndaflexAndromaco
IndocidLundbeck
Indolar SRSandoz
IndomedGreater Pharma
IndoxenQuality Pharmaceutical
MetindolGlaxoSmithKline
MikametanMikasa Seiyaku
Nu-IndoNu-Pharm
ReumacideVitória
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Indomethacin sodium
ThumbNot applicableDBSALT001435
Categories
UNIIXXE1CET956
CAS number53-86-1
WeightAverage: 357.788
Monoisotopic: 357.076785712
Chemical FormulaC19H16ClNO4
InChI KeyInChIKey=CGIGDMFJXJATDK-UHFFFAOYSA-N
InChI
InChI=1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)
IUPAC Name
2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetic acid
SMILES
COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzoylindoles. These are organic compounds containing an indole attached to a benzoyl moiety through the acyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIndoles and derivatives
Sub ClassBenzoylindoles
Direct ParentBenzoylindoles
Alternative Parents
Substituents
  • Benzoylindole
  • Indole-3-acetic acid derivative
  • Indolyl carboxylic acid derivative
  • Indolecarboxylic acid derivative
  • Hydroxyindole
  • 4-halobenzoic acid or derivatives
  • Indole
  • Benzoic acid or derivatives
  • Benzoyl
  • Anisole
  • Halobenzene
  • Chlorobenzene
  • Alkyl aryl ether
  • Benzenoid
  • Substituted pyrrole
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Pyrrole
  • Carboxamide group
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Ether
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor moderate to severe rheumatoid arthritis including acute flares of chronic disease, ankylosing spondylitis, osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis.
PharmacodynamicsIndomethacin, a NSAIA, with analgesic and antipyretic properties exerts its pharmacological effects by inhibiting the synthesis of prostaglandins involved in pain, fever, and inflammation. Indomethacin inhibits the catalytic activity of the COX enzymes, the enzymes responsible for catalyzing the rate-limiting step in prostaglandin synthesis via the arachidonic acid pathway. Indomethacin is known to inhibit two well-characterized isoforms of COX, COX-1 and COX-2, with greater selectivity for COX-1. COX-1 is a constitutively expressed enzyme that is involved in gastric mucosal protection, platelet and kidney function. It catalyzes the conversion of arachidonic acid to prostaglandin (PG) G2 and PGG2 to PGH2. COX-1 is involved in the synthesis pathways of PGE2, PGD2, PDF2a, PGI2 (also known as prostacyclin) and thromboxane A2 (TXA2). COX-2 is constitutively expressed and highly inducible by inflammatory stimuli. It is found in the central nervous system, kidneys, uterus and other organs. It also catalyzes the conversion of arachidonic acid to PGG2 and PGG2 to PGH2. In the COX-2-mediated pathway, PGH2 is subsequently converted to PGE2 and PGI2 (also known as prostacyclin). PGE2 is involved in mediating inflammation, pain and fever. Decreasing levels of PGE2 leads to decreased inflammation.
Mechanism of actionIndomethacin is a prostaglandin G/H synthase (also known as cyclooxygenase or COX) inhibitor that acts on both prostaglandin G/H synthase 1 and 2 (COX-1 and -2). Prostaglandin G/H synthase catalyzes the conversion of arachidonic acid to a number of prostaglandins involved in fever, pain, swelling, inflammation, and platelet aggregation. Indomethacin antagonizes COX by binding to the upper portion of the active site, preventing its substrate, arachidonic acid, from entering the active site. Indomethacin, unlike other NSAIDs, also inhibits phospholipase A2, the enzyme responsible for releasing arachidonic acid from phospholipids. Indomethacin is more selective for COX-1 than COX-2, which accounts for its increased adverse gastric effects relative to other NSAIDs. COX-1 is required for maintaining the protective gastric mucosal layer. The analgesic, antipyretic and anti-inflammatory effects of indomethacin occur as a result of decreased prostaglandin synthesis. Its antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation.
Related Articles
AbsorptionBioavailability is approximately 100% following oral administration and 80–90% following rectal administration.
Volume of distributionNot Available
Protein binding97%
Metabolism

Hepatic.

SubstrateEnzymesProduct
Indomethacin
O-DesmethylindomethacinDetails
Indomethacin
Indomethacin acyl glucuronideDetails
Indomethacin
N-Deschlorobenzoyl indomethacinDetails
N-Deschlorobenzoyl indomethacin
Not Available
O-Desmethyl-N-deschlorobenzoyl indomethacinDetails
Route of eliminationIndomethacin is eliminated via renal excretion, metabolism, and biliary excretion.
Half life4.5 hours
ClearanceNot Available
ToxicityThe following symptoms may be observed following overdosage: nausea, vomiting, intense headache, dizziness, mental confusion, disorientation, or lethargy. There have been reports of paresthesias, numbness, and convulsions. The oral LD50 of indomethacin in mice and rats (based on 14 day mortality response) was 50 and 12 mg/kg, respectively.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Indomethacin Action PathwayDrug actionSMP00104
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9509
Blood Brain Barrier+0.9381
Caco-2 permeable+0.5857
P-glycoprotein substrateNon-substrate0.636
P-glycoprotein inhibitor INon-inhibitor0.9313
P-glycoprotein inhibitor IINon-inhibitor0.834
Renal organic cation transporterNon-inhibitor0.8334
CYP450 2C9 substrateNon-substrate0.712
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6436
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9302
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6978
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8728
BiodegradationNot ready biodegradable0.9743
Rat acute toxicity4.0722 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9818
hERG inhibition (predictor II)Non-inhibitor0.8306
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Iroko pharmaceuticals llc
  • Sandoz inc
  • Able laboratories inc
  • Avanthi inc
  • Inwood laboratories inc sub forest laboratories inc
  • Teva pharmaceuticals usa inc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Halsey drug co inc
  • Heritage pharmaceuticals inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Parke davis div warner lambert co
  • Pioneer pharmaceuticals inc
  • Pliva inc
  • Roxane laboratories inc
  • Superpharm corp
  • Vintage pharmaceuticals llc
  • Watson laboratories inc
  • App pharmaceuticals llc
  • G and w laboratories inc
  • Lundbeck inc
  • Bedford laboratories div ben venue laboratories inc
Packagers
Dosage forms
FormRouteStrength
Capsuleoral25 mg
Capsuleoral50 mg
Capsule (sustained-release)oral75 mg
Dropsophthalmic10 mg
Suspensionoral25 mg/5mL
Liquid; powder for solutionophthalmic1 mg
Capsuleoral25 mg/1
Capsuleoral50 mg/1
Capsule, extended releaseoral75 mg/1
Injection, powder, lyophilized, for solutionintravenous1 mg/mL
Suppositoryrectal50 mg/1
Capsuleoral75 mg/1
Suppositoryrectal100 mg
Suppositoryrectal50 mg
Capsuleoral20 mg/1
Capsuleoral40 mg/1
Prices
Unit descriptionCostUnit
Indocin i.v. 1 mg vial642.6USD vial
Indomethacin 1 mg vial600.0USD vial
Indocin 50 mg suppository9.56USD suppository
Indomethacin CR 75 mg capsule3.12USD capsule
Indocin sr 75 mg capsule2.92USD capsule
Indomethacin powder2.57USD g
Ratio-Indomethacin 100 mg Suppository0.93USD suppository
Sandoz Indomethacin 100 mg Suppository0.93USD suppository
Sandoz Indomethacin 50 mg Suppository0.93USD suppository
Indomethacin 50 mg capsule0.65USD capsule
Indomethacin 25 mg capsule0.44USD capsule
Apo-Indomethacin 50 mg Capsule0.16USD capsule
Novo-Methacin 50 mg Capsule0.16USD capsule
Nu-Indo 50 mg Capsule0.16USD capsule
Apo-Indomethacin 25 mg Capsule0.09USD capsule
Novo-Methacin 25 mg Capsule0.09USD capsule
Nu-Indo 25 mg Capsule0.09USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8734847 No2010-04-232030-04-23Us
US8992982 No2010-04-232030-04-23Us
US9089471 No2010-04-232030-04-23Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point151U.S. Patent 3,161,654.
water solubility0.937 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.27HANSCH,C ET AL. (1995)
logS-4.62ADME Research, USCD
Caco2 permeability-4.69ADME Research, USCD
pKa4.5BUDAVARI,S ET AL. (1989)
Predicted Properties
PropertyValueSource
Water Solubility0.0024 mg/mLALOGPS
logP4.25ALOGPS
logP3.53ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)3.8ChemAxon
pKa (Strongest Basic)-2.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area68.53 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity94.81 m3·mol-1ChemAxon
Polarizability36.64 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.7 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-000i-1901000000-710010c41f0ded9b0f17View in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
References
Synthesis Reference

Hubertus L. Regtop, John R. Biffin, “Preparation of divalent metal salts of indomethacin.” U.S. Patent US5310936, issued November, 1917.

US5310936
General References
  1. Akbarpour F, Afrasiabi A, Vaziri ND: Severe hyperkalemia caused by indomethacin and potassium supplementation. South Med J. 1985 Jun;78(6):756-7. [PubMed:4002013 ]
  2. HART FD, BOARDMAN PL: INDOMETHACIN: A NEW NON-STEROID ANTI-INFLAMMATORY AGENT. Br Med J. 1963 Oct 19;2(5363):965-70. [PubMed:14056924 ]
  3. Lum GM, Aisenbrey GA, Dunn MJ, Berl T, Schrier RW, McDonald KM: In vivo effect of indomethacin to potentiate the renal medullary cyclic AMP response to vasopressin. J Clin Invest. 1977 Jan;59(1):8-13. [PubMed:187624 ]
  4. Phelan KM, Mosholder AD, Lu S: Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs. J Clin Psychiatry. 2003 Nov;64(11):1328-34. [PubMed:14658947 ]
  5. Ragheb M: The clinical significance of lithium-nonsteroidal anti-inflammatory drug interactions. J Clin Psychopharmacol. 1990 Oct;10(5):350-4. [PubMed:2258452 ]
External Links
ATC CodesS01CC02M02AA23M01AB01M01AB51C01EB03S01BC01
AHFS Codes
  • 28:08.04.92
PDB EntriesNot Available
FDA labelDownload (56.2 KB)
MSDSDownload (73.2 KB)
Interactions
Drug Interactions
Drug
AbciximabIndomethacin may increase the anticoagulant activities of Abciximab.
AbirateroneThe metabolism of Indomethacin can be decreased when combined with Abiraterone.
AcebutololIndomethacin may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Indomethacin is combined with Aceclofenac.
AcenocoumarolIndomethacin may increase the anticoagulant activities of Acenocoumarol.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Indomethacin.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Indomethacin is combined with Acetylsalicylic acid.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Indomethacin.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Indomethacin.
AlbendazoleThe serum concentration of Indomethacin can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Indomethacin can be decreased when it is combined with Aldosterone.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Indomethacin.
AlectinibThe serum concentration of Indomethacin can be increased when it is combined with Alectinib.
Alendronic acidThe risk or severity of adverse effects can be increased when Indomethacin is combined with Alendronic acid.
AlfentanilThe serum concentration of Indomethacin can be increased when it is combined with Alfentanil.
AliskirenIndomethacin may decrease the antihypertensive activities of Aliskiren.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Indomethacin.
AlprenololIndomethacin may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Indomethacin.
AmantadineThe serum concentration of Indomethacin can be increased when it is combined with Amantadine.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Indomethacin.
AmikacinIndomethacin may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideIndomethacin may decrease the antihypertensive activities of Amiloride.
Aminohippuric acidThe serum concentration of Indomethacin can be increased when it is combined with Aminohippuric acid.
AmiodaroneThe serum concentration of Indomethacin can be decreased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Indomethacin.
AmlodipineThe serum concentration of Indomethacin can be increased when it is combined with Amlodipine.
AmprenavirThe serum concentration of Indomethacin can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Indomethacin can be increased when it is combined with Amsacrine.
AncrodIndomethacin may increase the anticoagulant activities of Ancrod.
AntipyrineThe risk or severity of adverse effects can be increased when Indomethacin is combined with Antipyrine.
Antithrombin III humanIndomethacin may increase the anticoagulant activities of Antithrombin III human.
ApixabanIndomethacin may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Indomethacin is combined with Apremilast.
AprepitantThe metabolism of Indomethacin can be increased when combined with Aprepitant.
ArdeparinIndomethacin may increase the anticoagulant activities of Ardeparin.
ArgatrobanIndomethacin may increase the anticoagulant activities of Argatroban.
ArmodafinilThe metabolism of Indomethacin can be decreased when combined with Armodafinil.
ArotinololIndomethacin may decrease the antihypertensive activities of Arotinolol.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Indomethacin.
AstemizoleThe serum concentration of Indomethacin can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Indomethacin.
AtenololIndomethacin may decrease the antihypertensive activities of Atenolol.
AtenololThe serum concentration of Indomethacin can be increased when it is combined with Atenolol.
AtorvastatinThe serum concentration of Indomethacin can be increased when it is combined with Atorvastatin.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Indomethacin.
AzapropazoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Indomethacin is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Indomethacin.
AzithromycinThe serum concentration of Indomethacin can be increased when it is combined with Azithromycin.
BalsalazideIndomethacin may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Indomethacin.
BecaplerminIndomethacin may increase the anticoagulant activities of Becaplermin.
BefunololIndomethacin may decrease the antihypertensive activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Indomethacin.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Indomethacin.
BenoxaprofenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Benoxaprofen.
BenzocaineThe serum concentration of Indomethacin can be increased when it is combined with Benzocaine.
BepridilThe serum concentration of Indomethacin can be increased when it is combined with Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Indomethacin.
BetaxololIndomethacin may decrease the antihypertensive activities of Betaxolol.
BevantololIndomethacin may decrease the antihypertensive activities of Bevantolol.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Indomethacin.
BiperidenThe serum concentration of Indomethacin can be increased when it is combined with Biperiden.
BisoprololIndomethacin may decrease the antihypertensive activities of Bisoprolol.
BivalirudinIndomethacin may increase the anticoagulant activities of Bivalirudin.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Indomethacin.
BopindololIndomethacin may decrease the antihypertensive activities of Bopindolol.
BortezomibThe metabolism of Indomethacin can be decreased when combined with Bortezomib.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Indomethacin.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Indomethacin.
BromfenacThe risk or severity of adverse effects can be increased when Indomethacin is combined with Bromfenac.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Indomethacin.
BufuralolIndomethacin may decrease the antihypertensive activities of Bufuralol.
BumetanideIndomethacin may decrease the diuretic activities of Bumetanide.
BupranololIndomethacin may decrease the antihypertensive activities of Bupranolol.
BuprenorphineThe serum concentration of Indomethacin can be increased when it is combined with Buprenorphine.
BuspironeThe serum concentration of Indomethacin can be increased when it is combined with Buspirone.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Indomethacin.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Indomethacin.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Indomethacin.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Indomethacin.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Indomethacin.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Indomethacin.
CapecitabineThe metabolism of Indomethacin can be decreased when combined with Capecitabine.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Indomethacin.
CarbamazepineThe serum concentration of Indomethacin can be decreased when it is combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Indomethacin.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Indomethacin.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Indomethacin.
CarprofenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Carprofen.
CarteololIndomethacin may decrease the antihypertensive activities of Carteolol.
CarvedilolIndomethacin may decrease the antihypertensive activities of Carvedilol.
CarvedilolThe serum concentration of Indomethacin can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Indomethacin can be increased when it is combined with Caspofungin.
CastanospermineThe risk or severity of adverse effects can be increased when Indomethacin is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Indomethacin is combined with Celecoxib.
CeliprololIndomethacin may decrease the antihypertensive activities of Celiprolol.
CeritinibThe serum concentration of Indomethacin can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Indomethacin.
CertoparinIndomethacin may increase the anticoagulant activities of Certoparin.
ChloramphenicolThe metabolism of Indomethacin can be decreased when combined with Chloramphenicol.
ChloroquineThe risk or severity of adverse effects can be increased when Indomethacin is combined with Chloroquine.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Indomethacin.
ChlorpromazineThe serum concentration of Indomethacin can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Indomethacin can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Indomethacin can be increased when it is combined with Chlorprothixene.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Indomethacin.
CholecalciferolThe metabolism of Indomethacin can be decreased when combined with Cholecalciferol.
CholesterolThe serum concentration of Indomethacin can be increased when it is combined with Cholesterol.
CholestyramineCholestyramine can cause a decrease in the absorption of Indomethacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cholic AcidThe serum concentration of Indomethacin can be decreased when it is combined with Cholic Acid.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Indomethacin.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Indomethacin.
CimetidineThe serum concentration of Indomethacin can be decreased when it is combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Indomethacin.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Indomethacin.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Indomethacin.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Indomethacin.
Citric AcidIndomethacin may increase the anticoagulant activities of Citric Acid.
ClarithromycinThe serum concentration of Indomethacin can be increased when it is combined with Clarithromycin.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Indomethacin.
ClodronateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Clodronate.
ClofazimineThe serum concentration of Indomethacin can be increased when it is combined with Clofazimine.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Indomethacin.
ClomipramineThe serum concentration of Indomethacin can be increased when it is combined with Clomipramine.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Indomethacin.
ClonixinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Clonixin.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Indomethacin.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Indomethacin.
ClotrimazoleThe serum concentration of Indomethacin can be decreased when it is combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Indomethacin.
CobicistatThe serum concentration of Indomethacin can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Indomethacin.
ColchicineThe serum concentration of Indomethacin can be increased when it is combined with Colchicine.
ColesevelamColesevelam can cause a decrease in the absorption of Indomethacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Indomethacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColforsinThe serum concentration of Indomethacin can be increased when it is combined with Colforsin.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Indomethacin.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Indomethacin.
CyclophosphamideThe serum concentration of Indomethacin can be increased when it is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Indomethacin can be decreased when it is combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Indomethacin.
D-LimoneneThe risk or severity of adverse effects can be increased when Indomethacin is combined with D-Limonene.
Dabigatran etexilateIndomethacin may increase the anticoagulant activities of Dabigatran etexilate.
DabrafenibThe serum concentration of Indomethacin can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Indomethacin.
DaclatasvirThe serum concentration of Indomethacin can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Indomethacin can be increased when it is combined with Dactinomycin.
DalteparinIndomethacin may increase the anticoagulant activities of Dalteparin.
DanaparoidIndomethacin may increase the anticoagulant activities of Danaparoid.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Indomethacin.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Indomethacin.
DaunorubicinIndomethacin may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DaunorubicinThe serum concentration of Indomethacin can be decreased when it is combined with Daunorubicin.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Indomethacin.
DeferasiroxThe risk or severity of adverse effects can be increased when Indomethacin is combined with Deferasirox.
DelavirdineThe metabolism of Indomethacin can be decreased when combined with Delavirdine.
DesipramineThe serum concentration of Indomethacin can be increased when it is combined with Desipramine.
DesirudinIndomethacin may increase the anticoagulant activities of Desirudin.
DesloratadineThe serum concentration of Indomethacin can be increased when it is combined with Desloratadine.
DesmopressinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Desmopressin.
DexamethasoneThe serum concentration of Indomethacin can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Indomethacin.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Indomethacin.
DextranIndomethacin may increase the anticoagulant activities of Dextran.
Dextran 40Indomethacin may increase the anticoagulant activities of Dextran 40.
Dextran 70Indomethacin may increase the anticoagulant activities of Dextran 70.
Dextran 75Indomethacin may increase the anticoagulant activities of Dextran 75.
DextromethorphanThe serum concentration of Indomethacin can be increased when it is combined with Dextromethorphan.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Indomethacin.
DiclofenacThe risk or severity of adverse effects can be increased when Indomethacin is combined with Diclofenac.
DicoumarolIndomethacin may increase the anticoagulant activities of Dicoumarol.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Indomethacin.
DiflunisalThe risk or severity of adverse effects can be increased when Indomethacin is combined with Diflunisal.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Indomethacin.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Indomethacin.
DigoxinThe serum concentration of Indomethacin can be decreased when it is combined with Digoxin.
DihydroergotamineThe serum concentration of Indomethacin can be increased when it is combined with Dihydroergotamine.
DihydrostreptomycinIndomethacin may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Indomethacin.
DiltiazemThe serum concentration of Indomethacin can be increased when it is combined with Diltiazem.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Indomethacin.
DipyridamoleThe serum concentration of Indomethacin can be increased when it is combined with Dipyridamole.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Indomethacin.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Indomethacin.
DoxazosinThe serum concentration of Indomethacin can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Indomethacin can be increased when it is combined with Doxepin.
DoxorubicinIndomethacin may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DoxorubicinThe serum concentration of Indomethacin can be decreased when it is combined with Doxorubicin.
DronabinolThe serum concentration of Indomethacin can be increased when it is combined with Dronabinol.
DronedaroneThe serum concentration of Indomethacin can be increased when it is combined with Dronedarone.
DrospirenoneIndomethacin may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Indomethacin is combined with Droxicam.
Edetic AcidIndomethacin may increase the anticoagulant activities of Edetic Acid.
EdoxabanIndomethacin may increase the anticoagulant activities of Edoxaban.
EfavirenzThe metabolism of Indomethacin can be decreased when combined with Efavirenz.
ElbasvirThe serum concentration of Indomethacin can be increased when it is combined with Elbasvir.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Indomethacin.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Indomethacin.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Indomethacin.
EnoxaparinIndomethacin may increase the anticoagulant activities of Enoxaparin.
EnzalutamideThe serum concentration of Indomethacin can be increased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Indomethacin.
EpirizoleThe risk or severity of adverse effects can be increased when Indomethacin is combined with Epirizole.
EpirubicinIndomethacin may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneIndomethacin may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Indomethacin.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Indomethacin.
ErgonovineThe serum concentration of Indomethacin can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Indomethacin can be increased when it is combined with Ergotamine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Indomethacin.
ErythromycinThe serum concentration of Indomethacin can be decreased when it is combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Indomethacin.
Eslicarbazepine acetateThe metabolism of Indomethacin can be decreased when combined with Eslicarbazepine acetate.
EsmololIndomethacin may decrease the antihypertensive activities of Esmolol.
EsomeprazoleThe metabolism of Indomethacin can be decreased when combined with Esomeprazole.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Indomethacin.
EstramustineThe serum concentration of Indomethacin can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Indomethacin can be decreased when it is combined with Estriol.
EstriolThe serum concentration of Estriol can be increased when it is combined with Indomethacin.
EstroneThe serum concentration of Indomethacin can be decreased when it is combined with Estrone.
EstroneThe serum concentration of Estrone can be increased when it is combined with Indomethacin.
Etacrynic acidIndomethacin may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Indomethacin.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Indomethacin.
Ethyl biscoumacetateIndomethacin may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Indomethacin is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Indomethacin is combined with Etodolac.
EtofenamateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Etofenamate.
EtoposideThe serum concentration of Indomethacin can be increased when it is combined with Etoposide.
EtoricoxibThe risk or severity of adverse effects can be increased when Indomethacin is combined with Etoricoxib.
EtravirineThe serum concentration of Indomethacin can be increased when it is combined with Etravirine.
Evening primrose oilThe risk or severity of adverse effects can be increased when Indomethacin is combined with Evening primrose oil.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Indomethacin.
exisulindThe risk or severity of adverse effects can be increased when Indomethacin is combined with exisulind.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Indomethacin.
FelodipineThe serum concentration of Indomethacin can be increased when it is combined with Felodipine.
FenbufenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fenoprofen.
FentanylThe serum concentration of Indomethacin can be increased when it is combined with Fentanyl.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Indomethacin.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Indomethacin.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Indomethacin.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Indomethacin.
FloxuridineThe metabolism of Indomethacin can be decreased when combined with Floxuridine.
FluconazoleThe serum concentration of Indomethacin can be increased when it is combined with Fluconazole.
FlunixinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Flunixin.
FluorouracilThe metabolism of Indomethacin can be decreased when combined with Fluorouracil.
FluoxetineThe serum concentration of Indomethacin can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Indomethacin can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Indomethacin can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Indomethacin can be increased when it is combined with Flurazepam.
FlurbiprofenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Flurbiprofen.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Indomethacin.
FluvastatinThe metabolism of Indomethacin can be decreased when combined with Fluvastatin.
FluvoxamineThe serum concentration of Indomethacin can be increased when it is combined with Fluvoxamine.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Indomethacin.
Fondaparinux sodiumIndomethacin may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Indomethacin.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Indomethacin.
FosphenytoinThe metabolism of Indomethacin can be increased when combined with Fosphenytoin.
FramycetinIndomethacin may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideIndomethacin may decrease the diuretic activities of Furosemide.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Indomethacin.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Indomethacin.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Indomethacin.
GemfibrozilThe metabolism of Indomethacin can be decreased when combined with Gemfibrozil.
GenisteinThe serum concentration of Indomethacin can be increased when it is combined with Genistein.
GentamicinIndomethacin may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
Glucagon recombinantThe therapeutic efficacy of Glucagon recombinant can be decreased when used in combination with Indomethacin.
GlyburideThe serum concentration of Indomethacin can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Indomethacin can be increased when it is combined with Glycerol.
Gramicidin DThe serum concentration of Indomethacin can be increased when it is combined with Gramicidin D.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Indomethacin.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Indomethacin.
HaloperidolThe risk or severity of adverse effects can be increased when Indomethacin is combined with Haloperidol.
HaloperidolThe serum concentration of Indomethacin can be increased when it is combined with Haloperidol.
HeparinIndomethacin may increase the anticoagulant activities of Heparin.
HirulogIndomethacin may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when Indomethacin is combined with HMPL-004.
HydralazineIndomethacin may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Indomethacin.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Indomethacin.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Indomethacin.
Hygromycin BIndomethacin may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Ibandronate.
IbuprofenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Indomethacin is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Indomethacin is combined with Icatibant.
IdarubicinIndomethacin may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Indomethacin.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Indomethacin.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Indomethacin.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Indomethacin.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Indomethacin.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Indomethacin.
IndenololIndomethacin may decrease the antihypertensive activities of Indenolol.
IndinavirThe serum concentration of Indomethacin can be decreased when it is combined with Indinavir.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Indomethacin.
IndoprofenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Indomethacin.
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Indomethacin.
IsavuconazoniumThe serum concentration of Indomethacin can be increased when it is combined with Isavuconazonium.
IsoniazidThe metabolism of Indomethacin can be decreased when combined with Isoniazid.
IsoxicamThe risk or severity of adverse effects can be increased when Indomethacin is combined with Isoxicam.
ItraconazoleThe serum concentration of Indomethacin can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Indomethacin can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Indomethacin.
KanamycinIndomethacin may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Kebuzone.
KetamineThe serum concentration of Indomethacin can be increased when it is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Indomethacin.
KetoconazoleThe serum concentration of Indomethacin can be increased when it is combined with Ketoconazole.
KetoprofenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Indomethacin.
LabetalolIndomethacin may decrease the antihypertensive activities of Labetalol.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Indomethacin.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Indomethacin.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Indomethacin.
LapatinibThe serum concentration of Indomethacin can be increased when it is combined with Lapatinib.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Indomethacin.
LeflunomideThe risk or severity of adverse effects can be increased when Indomethacin is combined with Leflunomide.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Indomethacin.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Indomethacin.
LepirudinIndomethacin may increase the anticoagulant activities of Lepirudin.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Indomethacin.
LevobunololIndomethacin may decrease the antihypertensive activities of Levobunolol.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Indomethacin.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Indomethacin.
LevothyroxineThe serum concentration of Indomethacin can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Indomethacin can be increased when it is combined with Lidocaine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Indomethacin.
LiothyronineThe serum concentration of Indomethacin can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Indomethacin can be decreased when it is combined with Liotrix.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Indomethacin.
LithiumThe serum concentration of Lithium can be increased when it is combined with Indomethacin.
LomitapideThe serum concentration of Indomethacin can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Indomethacin.
LopinavirThe serum concentration of Indomethacin can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Indomethacin can be increased when it is combined with Loratadine.
LornoxicamThe risk or severity of adverse effects can be increased when Indomethacin is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Indomethacin.
LosartanThe serum concentration of Losartan can be increased when it is combined with Indomethacin.
LovastatinThe serum concentration of Indomethacin can be increased when it is combined with Lovastatin.
LoxoprofenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Indomethacin.
LuliconazoleThe serum concentration of Indomethacin can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Indomethacin can be decreased when it is combined with Lumacaftor.
LumiracoxibThe risk or severity of adverse effects can be increased when Indomethacin is combined with Lumiracoxib.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Magnesium salicylate.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Indomethacin.
MaprotilineThe serum concentration of Indomethacin can be increased when it is combined with Maprotiline.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Indomethacin.
MebendazoleThe serum concentration of Indomethacin can be increased when it is combined with Mebendazole.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Indomethacin is combined with Meclofenamic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Indomethacin is combined with Mefenamic acid.
MefloquineThe serum concentration of Indomethacin can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Indomethacin can be increased when it is combined with Megestrol acetate.
MeloxicamThe risk or severity of adverse effects can be increased when Indomethacin is combined with Meloxicam.
MeprobamateThe serum concentration of Indomethacin can be increased when it is combined with Meprobamate.
MesalazineIndomethacin may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Indomethacin.
MetamizoleThe risk or severity of adverse effects can be increased when Indomethacin is combined with Metamizole.
MethadoneThe serum concentration of Indomethacin can be increased when it is combined with Methadone.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Indomethacin.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Indomethacin.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Indomethacin.
MetipranololIndomethacin may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Indomethacin.
MetoprololIndomethacin may decrease the antihypertensive activities of Metoprolol.
MetoprololThe serum concentration of Indomethacin can be increased when it is combined with Metoprolol.
MetrizamideIndomethacin may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MibefradilThe serum concentration of Indomethacin can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Indomethacin can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Indomethacin can be decreased when it is combined with Midazolam.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Indomethacin.
MifepristoneThe serum concentration of Indomethacin can be decreased when it is combined with Mifepristone.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Indomethacin.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Indomethacin.
MitomycinThe serum concentration of Indomethacin can be increased when it is combined with Mitomycin.
MitoxantroneThe serum concentration of Indomethacin can be decreased when it is combined with Mitoxantrone.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Indomethacin.
MoclobemideThe metabolism of Indomethacin can be decreased when combined with Moclobemide.
ModafinilThe metabolism of Indomethacin can be decreased when combined with Modafinil.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Indomethacin.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Indomethacin.
MorphineThe serum concentration of Morphine can be increased when it is combined with Indomethacin.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Indomethacin is combined with Mycophenolate mofetil.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Indomethacin is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Nabumetone.
NadololIndomethacin may decrease the antihypertensive activities of Nadolol.
NadroparinIndomethacin may increase the anticoagulant activities of Nadroparin.
NaftifineThe risk or severity of adverse effects can be increased when Indomethacin is combined with Naftifine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Indomethacin.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Indomethacin.
NaltrexoneThe serum concentration of Indomethacin can be increased when it is combined with Naltrexone.
NaproxenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Naproxen.
NaringeninThe serum concentration of Indomethacin can be increased when it is combined with Naringenin.
NCX 4016The risk or severity of adverse effects can be increased when Indomethacin is combined with NCX 4016.
NefazodoneThe serum concentration of Indomethacin can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Indomethacin can be decreased when it is combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Indomethacin.
NeomycinIndomethacin may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NeostigmineThe serum concentration of Indomethacin can be increased when it is combined with Neostigmine.
NepafenacThe risk or severity of adverse effects can be increased when Indomethacin is combined with Nepafenac.
NetilmicinIndomethacin may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
NicardipineThe serum concentration of Indomethacin can be increased when it is combined with Nicardipine.
NifedipineThe serum concentration of Indomethacin can be decreased when it is combined with Nifedipine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Indomethacin.
Niflumic AcidThe risk or severity of adverse effects can be increased when Indomethacin is combined with Niflumic Acid.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Indomethacin.
NimesulideThe risk or severity of adverse effects can be increased when Indomethacin is combined with Nimesulide.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Indomethacin.
NisoldipineThe serum concentration of Indomethacin can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Indomethacin can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Indomethacin can be increased when it is combined with Nitrendipine.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Indomethacin.
NorethisteroneThe serum concentration of Indomethacin can be decreased when it is combined with Norethisterone.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Indomethacin.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Indomethacin.
OlopatadineThe risk or severity of adverse effects can be increased when Indomethacin is combined with Olopatadine.
OlsalazineIndomethacin may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Indomethacin.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Indomethacin.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Indomethacin.
OmeprazoleThe serum concentration of Indomethacin can be increased when it is combined with Omeprazole.
OrgoteinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Orgotein.
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Indomethacin.
OtamixabanIndomethacin may increase the anticoagulant activities of Otamixaban.
OxaprozinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Oxaprozin.
OxprenololIndomethacin may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Oxyphenbutazone.
P-NitrophenolThe serum concentration of Indomethacin can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Indomethacin can be increased when it is combined with Paclitaxel.
Palmitic AcidThe serum concentration of Indomethacin can be increased when it is combined with Palmitic Acid.
PamidronateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Pamidronate.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Indomethacin.
PantoprazoleThe serum concentration of Indomethacin can be increased when it is combined with Pantoprazole.
ParecoxibThe risk or severity of adverse effects can be increased when Indomethacin is combined with Parecoxib.
ParomomycinIndomethacin may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
ParoxetineThe serum concentration of Indomethacin can be increased when it is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Indomethacin.
PenbutololIndomethacin may decrease the antihypertensive activities of Penbutolol.
Pentosan PolysulfateIndomethacin may increase the anticoagulant activities of Pentosan Polysulfate.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Indomethacin.
PhenindioneIndomethacin may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe serum concentration of Indomethacin can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Indomethacin.
PhenprocoumonIndomethacin may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Phenylbutazone.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Indomethacin.
PhenytoinThe metabolism of Indomethacin can be increased when combined with Phenytoin.
PimecrolimusThe risk or severity of adverse effects can be increased when Indomethacin is combined with Pimecrolimus.
PimozideThe serum concentration of Indomethacin can be increased when it is combined with Pimozide.
PindololIndomethacin may decrease the antihypertensive activities of Pindolol.
PiretanideIndomethacin may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Pirfenidone.
PiroxicamThe risk or severity of adverse effects can be increased when Indomethacin is combined with Piroxicam.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Indomethacin.
Platelet Activating FactorThe serum concentration of Indomethacin can be decreased when it is combined with Platelet Activating Factor.
PlicamycinIndomethacin may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Indomethacin.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Indomethacin.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Indomethacin.
PosaconazoleThe serum concentration of Indomethacin can be increased when it is combined with Posaconazole.
PractololIndomethacin may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Indomethacin.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Indomethacin.
PrazosinThe serum concentration of Indomethacin can be increased when it is combined with Prazosin.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Indomethacin.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Indomethacin.
PrimidoneThe metabolism of Indomethacin can be increased when combined with Primidone.
ProbenecidThe serum concentration of Indomethacin can be increased when it is combined with Probenecid.
ProgesteroneThe serum concentration of Indomethacin can be decreased when it is combined with Progesterone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Indomethacin.
PromethazineThe serum concentration of Indomethacin can be increased when it is combined with Promethazine.
PropacetamolThe risk or severity of adverse effects can be increased when Indomethacin is combined with Propacetamol.
PropafenoneThe serum concentration of Indomethacin can be increased when it is combined with Propafenone.
PropranololIndomethacin may decrease the antihypertensive activities of Propranolol.
PropranololThe serum concentration of Indomethacin can be increased when it is combined with Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Indomethacin.
Protein CIndomethacin may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeIndomethacin may increase the anticoagulant activities of Protocatechualdehyde.
ProtriptylineThe serum concentration of Indomethacin can be increased when it is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Indomethacin.
PTC299The risk or severity of adverse effects can be increased when Indomethacin is combined with PTC299.
PuromycinIndomethacin may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
PyrimethamineThe metabolism of Indomethacin can be decreased when combined with Pyrimethamine.
QuercetinThe serum concentration of Indomethacin can be increased when it is combined with Quercetin.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Indomethacin.
QuinacrineThe serum concentration of Indomethacin can be increased when it is combined with Quinacrine.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Indomethacin.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Indomethacin.
QuinidineThe serum concentration of Indomethacin can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Indomethacin can be increased when it is combined with Quinine.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Indomethacin.
RanitidineThe serum concentration of Indomethacin can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Indomethacin.
ReboxetineThe serum concentration of Indomethacin can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Indomethacin can be increased when it is combined with Regorafenib.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Indomethacin.
ReserpineThe serum concentration of Indomethacin can be decreased when it is combined with Reserpine.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Indomethacin.
ResveratrolThe risk or severity of adverse effects can be increased when Indomethacin is combined with Resveratrol.
ReviparinIndomethacin may increase the anticoagulant activities of Reviparin.
RibostamycinIndomethacin may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RifampicinThe serum concentration of Indomethacin can be decreased when it is combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Indomethacin.
RifapentineThe metabolism of Indomethacin can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Indomethacin.
RilpivirineThe serum concentration of Indomethacin can be increased when it is combined with Rilpivirine.
RisedronateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Risedronate.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Indomethacin.
RitonavirThe serum concentration of Indomethacin can be decreased when it is combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Indomethacin.
RivaroxabanIndomethacin may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Indomethacin is combined with Rofecoxib.
RolapitantThe serum concentration of Indomethacin can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Indomethacin.
SalicylamideThe risk or severity of adverse effects can be increased when Indomethacin is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Indomethacin is combined with Salicylic acid.
SalsalateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Salsalate.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Indomethacin.
SaquinavirThe serum concentration of Indomethacin can be decreased when it is combined with Saquinavir.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Indomethacin.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Indomethacin.
ScopolamineThe serum concentration of Indomethacin can be increased when it is combined with Scopolamine.
SecobarbitalThe metabolism of Indomethacin can be increased when combined with Secobarbital.
SelegilineThe serum concentration of Indomethacin can be increased when it is combined with Selegiline.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Indomethacin.
SeratrodastThe risk or severity of adverse effects can be increased when Indomethacin is combined with Seratrodast.
SertralineThe serum concentration of Indomethacin can be increased when it is combined with Sertraline.
SildenafilThe metabolism of Indomethacin can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Indomethacin.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Indomethacin.
SimvastatinThe serum concentration of Indomethacin can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Indomethacin can be decreased when it is combined with Sirolimus.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Indomethacin.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Indomethacin.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Indomethacin.
SotalolIndomethacin may decrease the antihypertensive activities of Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Indomethacin.
SpectinomycinIndomethacin may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Indomethacin.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Indomethacin.
SpironolactoneIndomethacin may decrease the antihypertensive activities of Spironolactone.
SpironolactoneThe serum concentration of Indomethacin can be increased when it is combined with Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Indomethacin is combined with SRT501.
St. John's WortThe serum concentration of Indomethacin can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Indomethacin can be increased when it is combined with Staurosporine.
StiripentolThe metabolism of Indomethacin can be decreased when combined with Stiripentol.
StreptomycinIndomethacin may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinIndomethacin may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinThe serum concentration of Indomethacin can be decreased when it is combined with Streptozocin.
SulfadiazineThe metabolism of Indomethacin can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Indomethacin can be decreased when combined with Sulfamethoxazole.
SulfasalazineIndomethacin may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Indomethacin.
SulfinpyrazoneThe serum concentration of Indomethacin can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Indomethacin can be decreased when combined with Sulfisoxazole.
SulindacThe risk or severity of adverse effects can be increased when Indomethacin is combined with Sulindac.
SulodexideIndomethacin may increase the anticoagulant activities of Sulodexide.
SumatriptanThe serum concentration of Indomethacin can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Indomethacin can be increased when it is combined with Sunitinib.
SuprofenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Suprofen.
TacrineThe serum concentration of Indomethacin can be increased when it is combined with Tacrine.
TacrolimusIndomethacin may increase the nephrotoxic activities of Tacrolimus.
TacrolimusThe serum concentration of Indomethacin can be decreased when it is combined with Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Indomethacin.
TamoxifenThe serum concentration of Indomethacin can be decreased when it is combined with Tamoxifen.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Indomethacin.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Indomethacin.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Indomethacin.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Technetium Tc-99m Medronate.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Indomethacin.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Indomethacin.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Indomethacin.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Indomethacin.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Indomethacin.
TenofovirThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tenoxicam.
TepoxalinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tepoxalin.
TerazosinThe serum concentration of Indomethacin can be increased when it is combined with Terazosin.
TerfenadineThe serum concentration of Indomethacin can be increased when it is combined with Terfenadine.
TeriflunomideThe risk or severity of adverse effects can be increased when Indomethacin is combined with Teriflunomide.
TesmilifeneThe serum concentration of Indomethacin can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Indomethacin can be increased when it is combined with Testosterone.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tiaprofenic acid.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Indomethacin.
TiclopidineThe metabolism of Indomethacin can be decreased when combined with Ticlopidine.
TiludronateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tiludronate.
TimololIndomethacin may decrease the antihypertensive activities of Timolol.
TobramycinIndomethacin may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
TolbutamideThe metabolism of Indomethacin can be decreased when combined with Tolbutamide.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tolmetin.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Indomethacin.
TopiramateThe metabolism of Indomethacin can be decreased when combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Indomethacin.
TorasemideIndomethacin may decrease the diuretic activities of Torasemide.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Indomethacin.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Indomethacin.
TranilastThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tranilast.
TranylcypromineThe metabolism of Indomethacin can be decreased when combined with Tranylcypromine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Indomethacin.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Indomethacin.
TrazodoneThe serum concentration of Indomethacin can be decreased when it is combined with Trazodone.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Indomethacin.
TriamtereneIndomethacin may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Indomethacin.
TrifluoperazineThe serum concentration of Indomethacin can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Indomethacin can be increased when it is combined with Triflupromazine.
TrimethoprimThe serum concentration of Indomethacin can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Indomethacin can be increased when it is combined with Trimipramine.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Indomethacin is combined with Trisalicylate-choline.
TroleandomycinThe serum concentration of Indomethacin can be increased when it is combined with Troleandomycin.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Indomethacin.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Indomethacin.
ValdecoxibThe risk or severity of adverse effects can be increased when Indomethacin is combined with Valdecoxib.
Valproic AcidThe metabolism of Indomethacin can be decreased when combined with Valproic Acid.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Indomethacin.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Indomethacin.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Indomethacin.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Indomethacin.
VerapamilThe serum concentration of Indomethacin can be decreased when it is combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Indomethacin.
VinblastineThe serum concentration of Indomethacin can be decreased when it is combined with Vinblastine.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Indomethacin.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Indomethacin.
VincristineThe serum concentration of Indomethacin can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Indomethacin can be increased when it is combined with Vinorelbine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Indomethacin.
VoriconazoleThe metabolism of Indomethacin can be decreased when combined with Voriconazole.
WarfarinIndomethacin may increase the anticoagulant activities of Warfarin.
XimelagatranIndomethacin may increase the anticoagulant activities of Ximelagatran.
ZafirlukastThe metabolism of Indomethacin can be decreased when combined with Zafirlukast.
ZaltoprofenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Zaltoprofen.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Indomethacin.
ZileutonThe risk or severity of adverse effects can be increased when Indomethacin is combined with Zileuton.
ZimelidineThe serum concentration of Indomethacin can be increased when it is combined with Zimelidine.
Zoledronic acidThe risk or severity of adverse effects can be increased when Indomethacin is combined with Zoledronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Indomethacin is combined with Zomepirac.
Food Interactions
  • Avoid alcohol.
  • Take with food or antacids to reduce irritation.

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Bobadilla L RA, Perez-Alvarez V, Bracho Valdes I, Lopez-Sanchez P: Effect of pregnancy on the roles of nitric oxide and prostaglandins in 5-hydroxytryptamine-induced contractions in rat isolated thoracic and abdominal aorta. Clin Exp Pharmacol Physiol. 2005 Mar;32(3):202-9. [PubMed:15743404 ]
  2. Fornai M, Blandizzi C, Colucci R, Antonioli L, Bernardini N, Segnani C, Baragatti B, Barogi S, Berti P, Spisni R, Del Tacca M: Role of cyclooxygenases 1 and 2 in the modulation of neuromuscular functions in the distal colon of humans and mice. Gut. 2005 May;54(5):608-16. [PubMed:15831902 ]
  3. Higuchi K, Tominaga K, Watanabe T, Uno H, Shiba M, Sasaki E, Tanigawa T, Takashima T, Hamaguchi M, Oshitani N, Matsumoto T, Iwanaga Y, Fukuda T, Fujiwara Y, Arakawa T: Indomethacin, but not Helicobacter pylori, inhibits adaptive relaxation in isolated guinea-pig stomach. Drugs Exp Clin Res. 2004;30(5-6):235-41. [PubMed:15700751 ]
  4. Kundu N, Walser TC, Ma X, Fulton AM: Cyclooxygenase inhibitors modulate NK activities that control metastatic disease. Cancer Immunol Immunother. 2005 Oct;54(10):981-7. Epub 2005 May 13. [PubMed:15891886 ]
  5. Moth CW, Prusakiewicz JJ, Marnett LJ, Lybrand TP: Stereoselective binding of indomethacin ethanolamide derivatives to cyclooxygenase-1. J Med Chem. 2005 May 19;48(10):3613-20. [PubMed:15887968 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Armstrong PJ, Franklin DP, Carey DJ, Elmore JR: Suppression of experimental aortic aneurysms: comparison of inducible nitric oxide synthase and cyclooxygenase inhibitors. Ann Vasc Surg. 2005 Mar;19(2):248-57. [PubMed:15770365 ]
  2. Jerde TJ, Calamon-Dixon JL, Bjorling DE, Nakada SY: Celecoxib inhibits ureteral contractility and prostanoid release. Urology. 2005 Jan;65(1):185-90. [PubMed:15667901 ]
  3. Pilane CM, Labelle EF: Nitric oxide stimulated vascular smooth muscle cells undergo apoptosis induced in part by arachidonic acid derived eicosanoids. J Cell Physiol. 2005 Aug;204(2):423-7. [PubMed:15668944 ]
  4. Yokota A, Taniguchi M, Takahira Y, Tanaka A, Takeuchi K: Rofecoxib produces intestinal but not gastric damage in the presence of a low dose of indomethacin in rats. J Pharmacol Exp Ther. 2005 Jul;314(1):302-9. Epub 2005 Apr 14. [PubMed:15831440 ]
  5. Zhang GS, Fu YB, Xia M: [Proliferation inhibition effect of indomethacin on CML cells associated with down-regulation of phosphorylated STAT1/STAT5 and inhibition of COX-2 expression]. Zhonghua Xue Ye Xue Za Zhi. 2004 Dec;25(12):732-5. [PubMed:15730717 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Phospholipid binding
Specific Function:
Thought to participate in the regulation of the phospholipid metabolism in biomembranes including eicosanoid biosynthesis. Catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides.
Gene Name:
PLA2G2A
Uniprot ID:
P14555
Molecular Weight:
16082.525 Da
References
  1. Geisslinger, G., & Lötsch, J. (2004). Non-steroidal anti-inflammatory drugs. In Encyclopedic reference of molecular pharmacology (pp. 667-671). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
15-oxoprostaglandin 13-oxidase activity
Specific Function:
Functions as 15-oxo-prostaglandin 13-reductase and acts on 15-keto-PGE1, 15-keto-PGE2, 15-keto-PGE1-alpha and 15-keto-PGE2-alpha with highest activity towards 15-keto-PGE2. Overexpression represses transcriptional activity of PPARG and inhibits adipocyte differentiation (By similarity).
Gene Name:
PTGR2
Uniprot ID:
Q8N8N7
Molecular Weight:
38498.74 Da
References
  1. Wu YH, Ko TP, Guo RT, Hu SM, Chuang LM, Wang AH: Structural basis for catalytic and inhibitory mechanisms of human prostaglandin reductase PTGR2. Structure. 2008 Nov 12;16(11):1714-23. doi: 10.1016/j.str.2008.09.007. [PubMed:19000823 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
activator
General Function:
Zinc ion binding
Specific Function:
Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation...
Gene Name:
PPARG
Uniprot ID:
P37231
Molecular Weight:
57619.58 Da
References
  1. Cho MC, Lee HS, Kim JH, Choe YK, Hong JT, Paik SG, Yoon DY: A simple ELISA for screening ligands of peroxisome proliferator-activated receptor-gamma. J Biochem Mol Biol. 2003 Mar 31;36(2):207-13. [PubMed:12689521 ]
  2. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA: Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1997 Feb 7;272(6):3406-10. [PubMed:9013583 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Catalyzes the conversion of hemimercaptal, formed from methylglyoxal and glutathione, to S-lactoylglutathione. Involved in the regulation of TNF-induced transcriptional activity of NF-kappa-B. Required for normal osteoclastogenesis.
Gene Name:
GLO1
Uniprot ID:
Q04760
Molecular Weight:
20777.515 Da
References
  1. Sato S, Kwon Y, Kamisuki S, Srivastava N, Mao Q, Kawazoe Y, Uesugi M: Polyproline-rod approach to isolating protein targets of bioactive small molecules: isolation of a new target of indomethacin. J Am Chem Soc. 2007 Jan 31;129(4):873-80. [PubMed:17243824 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Prostaglandin j receptor activity
Specific Function:
Receptor for prostaglandin D2 (PGD2). Coupled to the G(i)-protein. Receptor activation may result in pertussis toxin-sensitive decreases in cAMP levels and Ca(2+) mobilization. PI3K signaling is also implicated in mediating PTGDR2 effects. PGD2 induced receptor internalization. CRTH2 internalization can be regulated by diverse kinases such as, PKC, PKA, ADRBK1/GRK2, GPRK5/GRK5 and GRK6. Recepto...
Gene Name:
PTGDR2
Uniprot ID:
Q9Y5Y4
Molecular Weight:
43267.15 Da
References
  1. Hata AN, Lybrand TP, Breyer RM: Identification of determinants of ligand binding affinity and selectivity in the prostaglandin D2 receptor CRTH2. J Biol Chem. 2005 Sep 16;280(37):32442-51. Epub 2005 Jul 19. [PubMed:16030019 ]
  2. Hata AN, Lybrand TP, Marnett LJ, Breyer RM: Structural determinants of arylacetic acid nonsteroidal anti-inflammatory drugs necessary for binding and activation of the prostaglandin D2 receptor CRTH2. Mol Pharmacol. 2005 Mar;67(3):640-7. Epub 2004 Nov 24. [PubMed:15563582 ]
  3. Mathiesen JM, Ulven T, Martini L, Gerlach LO, Heinemann A, Kostenis E: Identification of indole derivatives exclusively interfering with a G protein-independent signaling pathway of the prostaglandin D2 receptor CRTH2. Mol Pharmacol. 2005 Aug;68(2):393-402. Epub 2005 May 3. [PubMed:15870392 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleylethanolamide, a naturally occurring lipid that regulates satiety. Receptor for peroxisome proliferators such as hypolipidemic drugs and fatty acids. Regulates the peroxisomal beta-oxidation pathway of fa...
Gene Name:
PPARA
Uniprot ID:
Q07869
Molecular Weight:
52224.595 Da
References
  1. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA: Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1997 Feb 7;272(6):3406-10. [PubMed:9013583 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Triglyceride lipase activity
Specific Function:
Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acyl-CoA ester. Hydrolyzes the methyl ester group of cocaine to form benzoylecgonine. Catalyzes the transesterification of cocaine to form cocaethylene. Displays fatty acid ethyl ester synthase activity,...
Gene Name:
CES1
Uniprot ID:
P23141
Molecular Weight:
62520.62 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A9
Uniprot ID:
O60656
Molecular Weight:
59940.495 Da
References
  1. Mano Y, Usui T, Kamimura H: Contribution of UDP-glucuronosyltransferases 1A9 and 2B7 to the glucuronidation of indomethacin in the human liver. Eur J Clin Pharmacol. 2007 Mar;63(3):289-96. Epub 2007 Jan 24. [PubMed:17245571 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Is also able to catalyze the glucuronidation of 17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4-methylumbelliferone, 1-naph...
Gene Name:
UGT1A1
Uniprot ID:
P22309
Molecular Weight:
59590.91 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Mano Y, Usui T, Kamimura H: In vitro inhibitory effects of non-steroidal antiinflammatory drugs on UDP-glucuronosyltransferase 1A1-catalysed estradiol 3beta-glucuronidation in human liver microsomes. Biopharm Drug Dispos. 2005 Jan;26(1):35-9. [PubMed:15593333 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol suggests it may play an important role in regulating the level and activity of these potent and active estrogen metabolites. Is also active with androsterone, hyodeoxycholic acid and tetrachlorocatechol...
Gene Name:
UGT2B7
Uniprot ID:
P16662
Molecular Weight:
60694.12 Da
References
  1. Mano Y, Usui T, Kamimura H: Contribution of UDP-glucuronosyltransferases 1A9 and 2B7 to the glucuronidation of indomethacin in the human liver. Eur J Clin Pharmacol. 2007 Mar;63(3):289-96. Epub 2007 Jan 24. [PubMed:17245571 ]
  2. Mano Y, Usui T, Kamimura H: Inhibitory potential of nonsteroidal anti-inflammatory drugs on UDP-glucuronosyltransferase 2B7 in human liver microsomes. Eur J Clin Pharmacol. 2007 Feb;63(2):211-6. Epub 2007 Jan 3. [PubMed:17200831 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Bertucci C, Wainer IW: Improved chromatographic performance of a modified human albumin based stationary phase. Chirality. 1997;9(4):335-40. [PubMed:9275312 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocytes (By similarity).
Gene Name:
ABCC3
Uniprot ID:
O15438
Molecular Weight:
169341.14 Da
References
  1. Zelcer N, Saeki T, Reid G, Beijnen JH, Borst P: Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem. 2001 Dec 7;276(49):46400-7. [PubMed:11581266 ]
  2. Gedeon C, Behravan J, Koren G, Piquette-Miller M: Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta. 2006 Nov-Dec;27(11-12):1096-102. Epub 2006 Feb 3. [PubMed:16460798 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
May be an organic anion pump relevant to cellular detoxification.
Gene Name:
ABCC4
Uniprot ID:
O15439
Molecular Weight:
149525.33 Da
References
  1. Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P: The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9. Epub 2003 Jun 30. [PubMed:12835412 ]
  2. Bai J, Lai L, Yeo HC, Goh BC, Tan TM: Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimane-glutathione. Int J Biochem Cell Biol. 2004 Feb;36(2):247-57. [PubMed:14643890 ]
  3. Ose A, Ito M, Kusuhara H, Yamatsugu K, Kanai M, Shibasaki M, Hosokawa M, Schuetz JD, Sugiyama Y: Limited brain distribution of [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic anion transporter 3 (Oat3/Slc22a8) and multidrug resistance-associated protein 4 (Mrp4/Abcc4). Drug Metab Dispos. 2009 Feb;37(2):315-21. doi: 10.1124/dmd.108.024018. Epub 2008 Nov 24. [PubMed:19029202 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Isoform 1: May participate directly in the active transport of drugs into subcellular organelles or influence drug distribution indirectly. Transports glutathione conjugates as leukotriene-c4 (LTC4) and N-ethylmaleimide S-glutathione (NEM-GS).Isoform 2: Inhibits TNF-alpha-mediated apoptosis through blocking one or more caspases.
Gene Name:
ABCC6
Uniprot ID:
O95255
Molecular Weight:
164904.81 Da
References
  1. Ilias A, Urban Z, Seidl TL, Le Saux O, Sinko E, Boyd CD, Sarkadi B, Varadi A: Loss of ATP-dependent transport activity in pseudoxanthoma elasticum-associated mutants of human ABCC6 (MRP6). J Biol Chem. 2002 May 10;277(19):16860-7. Epub 2002 Mar 5. [PubMed:11880368 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514 ]
  2. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. [PubMed:12954186 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Evers R, de Haas M, Sparidans R, Beijnen J, Wielinga PR, Lankelma J, Borst P: Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83. [PubMed:10917554 ]
  2. Hong J, Lambert JD, Lee SH, Sinko PJ, Yang CS: Involvement of multidrug resistance-associated proteins in regulating cellular levels of (-)-epigallocatechin-3-gallate and its methyl metabolites. Biochem Biophys Res Commun. 2003 Oct 10;310(1):222-7. [PubMed:14511674 ]
  3. Ilias A, Urban Z, Seidl TL, Le Saux O, Sinko E, Boyd CD, Sarkadi B, Varadi A: Loss of ATP-dependent transport activity in pseudoxanthoma elasticum-associated mutants of human ABCC6 (MRP6). J Biol Chem. 2002 May 10;277(19):16860-7. Epub 2002 Mar 5. [PubMed:11880368 ]
  4. Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P: The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9. Epub 2003 Jun 30. [PubMed:12835412 ]
  5. Gedeon C, Behravan J, Koren G, Piquette-Miller M: Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta. 2006 Nov-Dec;27(11-12):1096-102. Epub 2006 Feb 3. [PubMed:16460798 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, Sugiyama Y: Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res. 2002 Feb;19(2):147-53. [PubMed:11883641 ]
  2. Kouzuki H, Suzuki H, Sugiyama Y: Pharmacokinetic study of the hepatobiliary transport of indomethacin. Pharm Res. 2000 Apr;17(4):432-8. [PubMed:10870987 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Mulato AS, Ho ES, Cihlar T: Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther. 2000 Oct;295(1):10-5. [PubMed:10991954 ]
  2. Jung KY, Takeda M, Kim DK, Tojo A, Narikawa S, Yoo BS, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 2001 Sep 21;69(18):2123-35. [PubMed:11669456 ]
  3. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730 ]
  4. Hosoyamada M, Sekine T, Kanai Y, Endou H: Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am J Physiol. 1999 Jan;276(1 Pt 2):F122-8. [PubMed:9887087 ]
  5. Lu R, Chan BS, Schuster VL: Cloning of the human kidney PAH transporter: narrow substrate specificity and regulation by protein kinase C. Am J Physiol. 1999 Feb;276(2 Pt 2):F295-303. [PubMed:9950961 ]
  6. Sandhu P, Lee W, Xu X, Leake BF, Yamazaki M, Stone JA, Lin JH, Pearson PG, Kim RB: Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos. 2005 May;33(5):676-82. Epub 2005 Feb 16. [PubMed:15716364 ]
  7. Kuze K, Graves P, Leahy A, Wilson P, Stuhlmann H, You G: Heterologous expression and functional characterization of a mouse renal organic anion transporter in mammalian cells. J Biol Chem. 1999 Jan 15;274(3):1519-24. [PubMed:9880528 ]
  8. Uwai Y, Saito H, Inui K: Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter. Eur J Pharmacol. 2000 Dec 1;409(1):31-6. [PubMed:11099697 ]
  9. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:
SLC22A8
Uniprot ID:
Q8TCC7
Molecular Weight:
59855.585 Da
References
  1. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. [PubMed:11306713 ]
  2. Jung KY, Takeda M, Kim DK, Tojo A, Narikawa S, Yoo BS, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 2001 Sep 21;69(18):2123-35. [PubMed:11669456 ]
  3. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730 ]
  4. Ohtsuki S, Kikkawa T, Mori S, Hori S, Takanaga H, Otagiri M, Terasaki T: Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier. J Pharmacol Exp Ther. 2004 Jun;309(3):1273-81. Epub 2004 Feb 4. [PubMed:14762099 ]
  5. Mori S, Takanaga H, Ohtsuki S, Deguchi T, Kang YS, Hosoya K, Terasaki T: Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells. J Cereb Blood Flow Metab. 2003 Apr;23(4):432-40. [PubMed:12679720 ]
  6. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Gedeon C, Behravan J, Koren G, Piquette-Miller M: Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta. 2006 Nov-Dec;27(11-12):1096-102. Epub 2006 Feb 3. [PubMed:16460798 ]
  2. Dahan A, Amidon GL: Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7. doi: 10.1152/ajpgi.00102.2009. Epub 2009 Jun 18. [PubMed:19541926 ]
  3. Dahan A, Sabit H, Amidon GL: The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport. AAPS J. 2009 Jun;11(2):205-13. doi: 10.1208/s12248-009-9092-5. Epub 2009 Mar 25. [PubMed:19319690 ]
  4. Kouzuki H, Suzuki H, Sugiyama Y: Pharmacokinetic study of the hepatobiliary transport of indomethacin. Pharm Res. 2000 Apr;17(4):432-8. [PubMed:10870987 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Purine nucleotide transmembrane transporter activity
Specific Function:
Participates in physiological processes involving bile acids, conjugated steroids and cyclic nucleotides. Enhances the cellular extrusion of cAMP and cGMP. Stimulates the ATP-dependent uptake of a range of physiological and synthetic lipophilic anions, including the glutathione S-conjugates leukotriene C4 and dinitrophenyl S-glutathione, steroid sulfates such as dehydroepiandrosterone 3-sulfate...
Gene Name:
ABCC11
Uniprot ID:
Q96J66
Molecular Weight:
154299.625 Da
References
  1. Chen ZS, Guo Y, Belinsky MG, Kotova E, Kruh GD: Transport of bile acids, sulfated steroids, estradiol 17-beta-D-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11). Mol Pharmacol. 2005 Feb;67(2):545-57. Epub 2004 Nov 10. [PubMed:15537867 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name:
SLC22A11
Uniprot ID:
Q9NSA0
Molecular Weight:
59970.945 Da
References
  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Enomoto A, Tojo A, Cha SH, Sekine T, Sakthisekaran D, Endou H: Role of human organic anion transporter 4 in the transport of ochratoxin A. Biochim Biophys Acta. 2002 Jun 12;1590(1-3):64-75. [PubMed:12063169 ]
  2. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730 ]
  3. Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, Kim DK, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem. 2000 Feb 11;275(6):4507-12. [PubMed:10660625 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Virus receptor activity
Specific Function:
The hepatic sodium/bile acid uptake system exhibits broad substrate specificity and transports various non-bile acid organic compounds as well. It is strictly dependent on the extracellular presence of sodium.(Microbial infection) Acts as a receptor for hepatitis B virus.
Gene Name:
SLC10A1
Uniprot ID:
Q14973
Molecular Weight:
38118.64 Da
References
  1. Kouzuki H, Suzuki H, Sugiyama Y: Pharmacokinetic study of the hepatobiliary transport of indomethacin. Pharm Res. 2000 Apr;17(4):432-8. [PubMed:10870987 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.
Gene Name:
SLC22A7
Uniprot ID:
Q9Y694
Molecular Weight:
60025.025 Da
References
  1. Morita N, Kusuhara H, Sekine T, Endou H, Sugiyama Y: Functional characterization of rat organic anion transporter 2 in LLC-PK1 cells. J Pharmacol Exp Ther. 2001 Sep;298(3):1179-84. [PubMed:11504818 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 25, 2016 02:16